The SPC839 is a dual inhibitor of AP-1 and NF-κB, showed good inhibitory activity against nitric oxide, TNF-α and FLT3, which is a potential target for acute myeloid leukemia (AML) (Figure 2E) (81, 82). This evidence concerns the gene NFKB1 and acute myeloid leukemia.